Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (20077)	5/5/1998 10:52:00 AM
From: squetch	Respond to of 32384

>>The anti-angiogenesis approach is not new<< Neither is Folkman's "closing in" on curing cancer according to jjc's comments yesterday.

To: Henry Niman who wrote (20077)	5/5/1998 12:51:00 PM
From: David Bogdanoff	Read Replies (2) \| Respond to of 32384

HN: Anti-angiogenesis approach has been around for 25 years according to analyst on CNBC this morning. He dropped his rating to neutral simply based on valuation. Other commentators on CNBC stressed that a drug that works in an animal will not necessarily work well or at all or safely in humans. There is a long way to go before there is proof of principle in humans. Apparently 25 years has not been long enough to give a answers to a number of important questions. David